Citations

Clear

16280 citation(s) found for "Yu, David".

Short-Term Cardiac and Noncardiac Mortality Following Liver Transplantation
Eleid, Mackram F. , Hurst, R. Todd, Vargas, Hugo E. , Rakela, Jorge , Appleton, Christopher P., Mulligan, David C. , Vargas, Hugo E

Mayo Clinic

Journal of Transplantation | August 12, 2010 | Volume: 2010 | Issue: No issue available | Pages: 1-7

10.1155/2010/910165 | PMID 20814597 Get It

Objectives. To determine the importance of acute cardiac events as a cause of mortality compared to non-cardiac events in the four month period following liver transplantation (LT) using current preoperative cardiac screening strategies.Patients and Methods. We retrospectively reviewed timing, type, and outcome of adverse cardiac events, and all cause mortality in the 4 month postoperative period in 393 consecutive LT patients from October 1999 to February 2008.Results. Of 30 total deaths (7.6% overall mortality rate), 27 (90%) were due to surgical or medical complications and 3 (10%) were primary cardiac deaths (0.8% cardiac mortality rate). Acute cardiac events occurred in 26 patients (6.6%), including 13 arrhythmias (50%), 7 new onset heart failures (27%), and 6 myocardial infarctions (23%). Twelve of 13 intraoperative events were arrhythmias (92%) including two of three cardiac deaths.Conclusions. Using current preoperative screening recommendations, deaths from primary cardiac events within four months of LT are very uncommon (0.8%), especially compared with deaths related to medical and surgical complications (6.9%).
Mutations in the Stalk Region of the Measles Virus Hemagglutinin Inhibit Syncytium Formation but Not Virus Entry
Ennis, Matthew K., Hu, Chunling , Naik, Shruthi , Hallak, Louay K. , Peng, Kah Whye, Russell, Stephen J. , Dingli, David , Russell, Stephen J , Hu, Chunling , Dingli, David

Mayo Clinic

Journal of Virology | August 12, 2010 | Volume: 84 | Issue: 20 | Pages: 10913-10917

10.1128/jvi.00789-10 | PMID 20702637 Get It

ABSTRACT Measles virus (MV) entry requires at least 2 viral proteins, the hemagglutinin (H) and fusion (F) proteins. We describe the rescue and characterization of a measles virus with a specific mutation in the stalk region of H (I98A) that is able to bind normally to cells but infects at a lower rate than the wild type due to a reduction in fusion triggering. The mutant H protein binds to F more avidly than the parent H protein does, and the corresponding virus is more sensitive to inhibition by fusion-inhibitory peptide. We show that after binding of MV to its receptor, H-F dissociation is required for productive infection.
Coordination of Substrate Binding and ATP Hydrolysis in Vps4-Mediated ESCRT-III Disassembly
Davies, Brian A., Azmi, Ishara F. , Payne, Johanna A., Shestakova, Anna , Horazdovsky, Bruce , Babst, Markus , Katzmann, David J.

Mayo Clinic

Molecular Biology of the Cell | August 12, 2010 | Volume: 21 | Issue: 19 | Pages: 3396-3408

10.1091/mbc.e10-06-0512 | PMID 20702581 Get It

ESCRT-III undergoes dynamic assembly and disassembly to facilitate membrane exvagination processes including multivesicular body (MVB) formation, enveloped virus budding, and membrane abscission during cytokinesis. The AAA-ATPase Vps4 is required for ESCRT-III disassembly, however the coordination of Vps4 ATP hydrolysis with ESCRT-III binding and disassembly is not understood. Vps4 ATP hydrolysis has been proposed to execute ESCRT-III disassembly as either a stable oligomer or an unstable oligomer whose dissociation drives ESCRT-III disassembly. An in vitro ESCRT-III disassembly assay was developed to analyze Vps4 function during this process. The studies presented here support a model in which Vps4 acts as a stable oligomer during ATP hydrolysis and ESCRT-III disassembly. Moreover, Vps4 oligomer binding to ESCRT-III induces coordination of ATP hydrolysis at the level of individual Vps4 subunits. These results suggest that Vps4 functions as a stable oligomer that acts upon individual ESCRT-III subunits to facilitate ESCRT-III disassembly.
HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
Perez, Edith A. , Reinholz, Monica M., Tenner, Kathleen , Schroeder, Matthew, Davidson, Nancy E. , Martino, Silvana, Harris, Lyndsay N. , Dueck, Amylou C. , Ketterling, Rhett P. , Lingle, Wilma L., Visscher, Daniel W., Jenkins, Robert B. , Hillman, David W. , Sledge, George W. , Gralow, Julie R. , Ingle, James N. , Kaufman, Peter A. , Dueck, A. C. , Ketterling, Rhett P

Mayo Clinic

Journal of Clinical Oncology | August 10, 2010 | Volume: 28 | Issue: 28 | Pages: 4307-4315

10.1200/jco.2009.26.2154 | PMID 20697084 Get It

Purpose We examined associations between tumor characteristics (human epidermal growth factor receptor 2 [HER2] protein expression, HER2 gene and chromosome 17 copy number, hormone receptor status) and disease-free survival (DFS) of patients in the N9831 adjuvant trastuzumab trial. Patients and Methods All patients (N = 1,888) underwent chemotherapy with doxorubicin and cyclophosphamide, followed by weekly paclitaxel with or without concurrent trastuzumab. HER2 status was determined by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) at a central laboratory, Mayo Clinic, Rochester, MN. Patients with conflicting local positive HER2 expression results but normal central laboratory testing were included in the analyses (n = 103). Results Patients with HER2-positive tumors (IHC 3+, FISH HER2/centromere 17 ratio ≥ 2.0, or both) benefited from trastuzumab, with hazard ratios (HRs) of 0.46, 0.49, and 0.45, respectively (all P < .0001). Patients with HER2-amplified tumors with polysomic (p17) or normal (n17) chromosome 17 copy number also benefited from trastuzumab, with HRs of 0.52 and 0.37, respectively (P < .006). Patients who received chemotherapy alone and had HER2-amplified and p17 tumors had a longer DFS than those who had n17 (78% v 68%; P = .04), irrespective of hormone receptor status or tumor grade. Patients with HER2-normal tumors by central testing (n = 103) seemed to benefit from trastuzumab, but the difference was not statistically significant (HR, 0.51; P = .14). Patients with hormone receptor–positive or –negative tumors benefited from the addition of trastuzumab, with HRs of 0.42 (P = .005) and 0.60 (P = .0001), respectively. Conclusion These results confirm that IHC or FISH HER2 testing is appropriate for patient selection for adjuvant trastuzumab therapy. Trastuzumab benefit seemed independent of HER2/centromere 17 ratio and chromosome 17 copy number.
Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorption
Mahadeo, Kris M. , Diop-Bove, Ndeye, Shin, Daniel Sanghoon , Unal, Ersin Selcuk, Teo, Juliana , Zhao, Rongbao, Chang, Min‐Hwang , Fulterer, Andreas, Romero, Michael F. , Goldman, I. David, Romero, Michael F

Mayo Clinic

American Journal of Physiology-Cell Physiology | August 5, 2010 | Volume: 299 | Issue: 5 | Pages: C1153-C1161

10.1152/ajpcell.00113.2010 | PMID 20686069 Get It

The proton-coupled folate transporter (PCFT-SLC46A1) is required for intestinal folate absorption and is mutated in the autosomal recessive disorder, hereditary folate malabsorption (HFM). This report characterizes properties and requirements of the R376 residue in PCFT function, including a R376Q mutant associated with HFM. Gln, Cys, and Ala substitutions resulted in markedly impaired transport of 5-formyltetrahydrofolate (5-FTHF) and 5-methyltetrahydrofolate (5-MTHF) due to an increase in Km and decrease in Vmax in HeLa R1–11 transfectants lacking endogenous folate transport function. In contrast, although the influx Km for pemetrexed was increased, transport was fully preserved at saturating concentrations and enhanced for the like-charged R376K- and R376H-PCFT. Pemetrexed and 5-FTHF influx mediated by R376Q-PCFT was markedly decreased at pH 5.5 compared with wild-type PCFT. However, while pemetrexed transport was substantially preserved at low pH (4.5–5.0), 5-FTHF transport remained very low. Electrophysiological studies in Xenopus oocytes demonstrated that 1) the R376Q mutant, like wild-type PCFT, transports protons in the absence of folate substrate, and in this respect has channel-like properties; and 2) the influx Km mediated by R376Q-PCFT is increased for 5-MTHF, 5-FTHF, and pemetrexed. The data suggest that mutation of the R376 residue to Gln impairs proton binding which, in turn, modulates the folate-binding pocket and depresses the rate of conformational alteration of the carrier, a change that appears to be, in part, substrate dependent.
EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy
Padeletti, Luigi, Arnar, Davíð O. , Boncinelli, Lorenzo, Brachman, J., Camm, A. John , Daubert, Jean‐Claude, Kassam, Shireen , Deliëns, Luc , Glikson, M., Hayes, David L. , Israel, Carsten W. , Lampert, Rachel , Lobban, Trudie, Raatikainen, Pekka , Siegal, Gene P. , Vardas, Panagiotis, Reviewers:, Kirchhof, Paulus , Becker, Ruediger, Cosío, Francisco G., Loh, Peter , Cobbe, Stuart M., Grace, Andrew A. , Morgan, John , Lobban, Trudie, Reviewers:, Kirchhof, Paulus

Mayo Clinic

Europace | July 31, 2010 | Volume: 12 | Issue: 10 | Pages: 1480-1489

10.1093/europace/euq275 | PMID 20675674 Get It

Abstract The purpose of this Consensus Statement is to focus on implantable cardioverter-defibrillator (ICD) deactivation in patients with irreversible or terminal illness. This statement summarizes the opinions of the Task Force members, convened by the European Heart Rhythm Association (EHRA) and the Heart Rhythm Society (HRS), based on ethical and legal principles, as well as their own clinical, scientific, and technical experience. It is directed to all healthcare professionals who treat patients with implanted ICDs, nearing end of life, in order to improve the patient dying process. This statement is not intended to recommend or promote device deactivation. Rather, the ultimate judgement regarding this procedure must be made by the patient (or in special conditions by his/her legal representative) after careful communication about the deactivation's consequences, respecting his/her autonomy and clarifying that he/she has a legal and ethical right to refuse it. Obviously, the physician asked to deactivate the ICD and the industry representative asked to assist can conscientiously object to and refuse to perform device deactivation.
Conference Report: Eighth Annual AACR International Conference on Frontiers in Cancer Prevention Research
Brewster, Abenaa M. , Patterson, Sherri, Forman, Michele R. , Wetter, David W. , Hawk, Ernest T. , Halbert, Chanita Hughes , Limburg, Paul J. , Ondrey, Frank G. , Paskett, Electra D.

Mayo Clinic

Cancer Prevention Research | July 28, 2010 | Volume: 3 | Issue: 8 | Pages: 1044-1048

10.1158/1940-6207.capr-10-0141 | PMID 20663980 Get It

Abstract The Eighth Annual Frontiers in Cancer Prevention Research meeting was held in Houston, Texas, in November 2009. This report highlights significant presentations that advance the fields of chemoprevention, clinical trial recruitment and retention, cancer screening including optical imaging, energy balance, and nutritional epidemiology, and health communications and decision making. In findings from the randomized Reduction by Dutasteride of Prostate Cancer Events trial, dutasteride reduced the risk of biopsy-detectable prostate cancer in high-risk men by 23% compared with placebo. Important clues about the dosing and window of susceptibility for supplementation with choline, vitamin D, and folate were revealed from epigenetic research that has implications for future nutritional epidemiology research. Noninvasive optical imaging techniques using endoscopic ultrasound and autofluorescence for the early detection of cancers in the lung, pancreas, and oral cavity are being studied. The report also addresses the challenges of promoting cancer prevention. Understanding how individuals process risk information and make sustained behavior changes and the effect of socioeconomic status on health disparities were identified as critical areas of research. This multidisciplinary research meeting of basic, clinical, and behavioral scientists and epidemiologists continues to play a major role in identifying the research priority areas of cancer prevention, elucidating new mechanisms of carcinogenesis for targeted chemoprevention therapies and delivering a comprehensive strategy for engaging individuals in the unifying goal to reduce cancer incidence. Cancer Prev Res; 3(8); 1044–8. ©2010 AACR.
Sodium Iodide Symporter (NIS)-Mediated Radiovirotherapy for Pancreatic Cancer
Penheiter, Alan R. , Wegman, Troy R., Classic, Kelly, Dingli, David , Bender, Claire E., Russell, Stephen J. , Carlson, Stephanie K., Russell, Stephen J , Dingli, David

Mayo Clinic

American Journal of Roentgenology | July 22, 2010 | Volume: 195 | Issue: 2 | Pages: 341-349

10.2214/ajr.09.3672 | PMID 20651188 Get It

Expression of LMO2 Is Associated With t(14;18)/IGH-BCL2 Fusion but Not BCL6 Translocations in Diffuse Large B-Cell Lymphoma
Durnick, David K., Maurer, Matthew J. , Natkunam, Yasodha , Levy, Ronald , Lossos, Izidore S. , Kurtin, Paul J. , McPhail, Ellen D. , Law, Mark E. , McPhail, Ellen Darcy , Maurer, Matthew , Natkunam, Yasodha

Mayo Clinic

American Journal of Clinical Pathology | July 21, 2010 | Volume: 134 | Issue: 2 | Pages: 278-281

10.1309/ajcpatup1d0hgcug | PMID 20660332 Get It

Abstract Diffuse large B-cell lymphoma (DLBCL) can be separated for prognostic purposes using gene expression profiling (GEP) into 2 subgroups: germinal center B-cell (GCB) and activated B-cell phenotypes. However, GEP is impractical for routine clinical use, and immunophenotyping is an imperfect surrogate. Therefore, we studied the relationship between expression of the purported germinal center marker LMO2 and the presence of IGH-BCL2 fusions, BCL6 translocations, and LMO2 translocations. In addition, we investigated the usefulness of LMO2 expression as a marker of GCB subtype in DLBCL. Immunohistochemical and fluorescence in situ hybridization studies were successfully performed on 101 cases of de novo DLBCL that had been incorporated into a tissue microarray. There was a statistically significant association between IGH-BCL2 fusion and LMO2 protein expression (P = .02) but not between BCL6 translocations and LMO2 expression. LMO2 translocations were not identified. Although uncommon, all cases that had both IGH-BCL2 fusion and BCL6 translocations expressed LMO2. The findings suggest LMO2 as a potential marker for the GCB phenotype.